24,452 results match your criteria American heart journal[Journal]


Extending physicians' reach in grasping AF symptoms.

Am Heart J 2020 May 4. Epub 2020 May 4.

Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.04.012DOI Listing

Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study.

Am Heart J 2020 Apr 4;224:192-200. Epub 2020 Apr 4.

University of Utah/Primary Children's Hospital, Salt Lake City, UT.

Background: Growth abnormalities in single-ventricle survivors may reduce quality of life (QoL) and exercise capacity.

Methods: This multicenter, longitudinal analysis evaluated changes in height and body mass index (BMI) compared to population norms and their relationship to mortality, ventricular morphology, QoL, and exercise capacity in the Pediatric Heart Network Fontan studies.

Results: Fontan 1 (F1) included 546 participants (12 ± 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.022DOI Listing

orth merican OVID-19 ST-segment elevation yocardial nfarction ( registry: Rationale, design, and implications.

Am Heart J 2020 May 16. Epub 2020 May 16.

The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH.

Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229476PMC

Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.

Am Heart J 2020 May 15. Epub 2020 May 15.

Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, NY, USA.

Using Mt. Sinai (New York City) EMR health system data, we retrospectively analyzed a cohort of 8438 COVID-19 patients seen between March 1st and April 22nd 2020. Risk of intubation and of death rose as a function of increasing age and as a function of greater cardiovascular comorbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227573PMC

Racial disparities and democratization of health care: A focus on TAVR in the United States.

Am Heart J 2020 Mar 13;224:166-170. Epub 2020 Mar 13.

Duke Clinical Research Institute and Duke University School of Medicine, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.008DOI Listing

A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.

Am Heart J 2020 May 3;225:3-9. Epub 2020 May 3.

Division of Cardiology and Duke Heart Center, Duke University Medical Center, Durham, NC.

The infection caused by severe acute respiratory syndrome coronavirus-2, or COVID-19, can result in myocardial injury, heart failure, and arrhythmias. In addition to the viral infection itself, investigational therapies for the infection can interact with the cardiovascular system. As cardiologists and cardiovascular service lines will be heavily involved in the care of patients with COVID-19, our division organized an approach to manage these complications, attempting to balance resource utilization and risk to personnel with optimal cardiovascular care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.04.024DOI Listing

Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE Trial): Rationale and design.

Am Heart J 2020 Feb 29;224:182-191. Epub 2020 Feb 29.

North Mississippi Medical Center, Tupelo, MS.

Atrial fibrillation is the most common sustained arrhythmia affecting over 33 million people worldwide. Approximately 70% of AF patients have non-paroxysmal AF. As AF progresses from paroxysmal to non-paroxysmal forms, the prevalence of comorbidities increases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.016DOI Listing
February 2020

Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement.

Am Heart J 2020 Apr 4;224:171-181. Epub 2020 Apr 4.

Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Fairfax, VA. Electronic address:

Background: Skeletal muscle wasting, or sarcopenia, affects a significant proportion of patients undergoing transcatheter aortic valve replacement (TAVR). However, its influence on post-TAVR recovery and 1-year health-related quality of life (HR-QOL) remains unknown. We examined the relationship between skeletal muscle index (SMI), post-TAVR length of hospital stay (LOS), and 1-year QOL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.021DOI Listing
April 2020
4.463 Impact Factor

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Am Heart J 2020 May 13. Epub 2020 May 13.

D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.

Background: Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.05.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219415PMC

Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.

Am Heart J 2020 Mar 25;224:156-165. Epub 2020 Mar 25.

Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:

Background: Although the need to detect restenosis has diminished in the contemporary practice of percutaneous coronary intervention (PCI) with drug-eluting stents (DES), the surveillance of ischemia owing to restenosis or disease progression deserves attention in high-risk PCI settings. It is unknown whether follow-up strategy of routine noninvasive functional testing potentially reduces the risk of major cardiovascular events in high-risk PCI patients.

Methods: The POST-PCI study is an investigator-initiated, multicenter, prospective randomized trial comparing the effectiveness of two follow-up strategies in patients with high-risk anatomic or clinical characteristics who underwent PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.019DOI Listing
March 2020
4.463 Impact Factor

Are cost advantages from a modern Indian hospital transferable to the United States?

Am Heart J 2020 Apr 21;224:148-155. Epub 2020 Apr 21.

Clinical Excellence Research Center, Stanford University, Stanford, CA. Electronic address:

Background: Multiple modern Indian hospitals operate at very low cost while meeting US-equivalent quality accreditation standards. Though US hospitals face intensifying pressure to lower their cost, including proposals to extend Medicare payment rates to all admissions, the transferability of Indian hospitals' cost advantages to US peers remains unclear.

Methods: Using time-driven activity-based costing methods, we estimate the average cost of personnel and space for an elective coronary artery bypass graft (CABG) surgery at two American hospitals and one Indian hospital (NH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.04.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194861PMC

Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".

Am Heart J 2020 May 6;223:110. Epub 2020 Mar 6.

Department of Surgery, Metropolitan Hospital Center, New York Medical College, Manhattan, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.001DOI Listing

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.

Am Heart J 2020 Jan 25;224:129-137. Epub 2020 Jan 25.

Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Background: Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute ST-segment-elevation myocardial infarction (STEMI).

Methods: In this double-blind, randomized, placebo-controlled trial patients with first STEMI were eligible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.012DOI Listing
January 2020

Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.

Am Heart J 2020 Mar 12;224:113-128. Epub 2020 Mar 12.

Department of Cardiology, University of Perugia, Perugia, Italy.

Heart failure (HF) management is challenging due to high clinical heterogeneity of this disease which makes patients responding differently to evidence-based standard therapy established by the current reductionist approach. Better understanding of the genetic and epigenetic interactions may clarify molecular signatures underlying maladaptive responses in HF, including metabolic shift, myocardial injury, fibrosis, and mitochondrial dysfunction. DNA methylation, histone modifications and micro-RNA (miRNAs) may be major epigenetic players in the pathogenesis of HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.007DOI Listing

Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.

Am Heart J 2020 Mar 19;224:98-104. Epub 2020 Mar 19.

Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, OH, USA.

Background: Randomized controlled trials (RCTs) have yielded conflicting results about the impact of transradial access (TRA) versus transfemoral access (TFA) in patients with ST-segment elevation myocardial infarction (STEMI).

Methods: We performed a trial sequential analysis (TSA) of RCTs comparing TRA and TFA in patients with STEMI. The outcomes of interest were 30-day mortality, major bleeding, major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, and access site complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.014DOI Listing

Transcatheter aortic valve replacement for patients with severe bicuspid aortic stenosis.

Am Heart J 2020 Feb 8;224:105-112. Epub 2020 Feb 8.

Department of Cardiology, Duke University Medical Center, Durham, NC. Electronic address:

Background: Patients with bicuspid aortic valve stenosis (BAV) were excluded from all the trileaflet aortic valve stenosis (TAV) pivotal trials, and therefore, their outcomes are not clearly defined. The aim of the study was to evaluate the outcomes of transcatheter aortic valve replacement (TAVR) in patients with BAV and compared them with those of TAV.

Methods: We evaluated the outcomes following TAVR of patients with BAV at our institution between April 2011 and November 2016 and compared them with the outcomes of patients with TAV treated with TAVR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.003DOI Listing
February 2020

Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?

Authors:
Jason N Katz

Am Heart J 2020 Mar 13. Epub 2020 Mar 13.

Department of Medicine, Division of Cardiology, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.006DOI Listing

Associations between anthropometric indices and outcomes of congenital heart operations in infants and young children: An analysis of data from the Society of Thoracic Surgeons Database.

Am Heart J 2020 Mar 19;224:85-97. Epub 2020 Mar 19.

Anesthesiology and Pain Medicine, Seattle Children's Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA.

Background: Children with congenital heart disease are at risk for growth failure due to inadequate nutrient intake and increased metabolic demands. We examined the relationship between anthropometric indices of nutrition (height-for-age z-score [HAZ], weight-for-age z-score [WAZ], weight-for-height z-score [WHZ]) and outcomes in a large sample of children undergoing surgery for congenital heart disease.

Methods: Patients in the Society of Thoracic Surgeons Congenital Heart Surgery Database having index cardiac surgery at age 1 month to 10 years were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.012DOI Listing

Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.

Am Heart J 2020 Mar 26;224:77-84. Epub 2020 Mar 26.

MedStar Heart and Vascular Institute, Washington Hospital Center, Washington, DC. Electronic address:

Background: Optimal transition care mitigates early hospital readmission risk. Given limited resources, hospitals need to identify patients with high readmission risk. This article examines whether a coordinated quality improvement campaign can help achieve this objective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.020DOI Listing

Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.

Am Heart J 2020 Mar 20;224:65-76. Epub 2020 Mar 20.

University of Washington, Seattle, WA.

Background: Whether androgen deficiency among men increases the risk of cardiovascular (CV) events or is merely a disease marker remains a subject of intense scientific interest.

Objectives: Among male subjects in the AIM-HIGH Trial with metabolic syndrome and low baseline levels of high-density lipoprotein (HDL)-cholesterol who were randomized to niacin or placebo plus simvastatin, we examined the relationship between low baseline testosterone (T) concentrations and subsequent CV outcomes during a mean 3-year follow-up.

Methods: In this post hoc analysis of men with available baseline plasma T concentrations, we examined the relationship between clinical/demographic characteristics and T concentrations both as a continuous and dichotomous variable (<300 ng/dL ["low T"] vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.016DOI Listing

Exploring the socioeconomic consequences of infective endocarditis.

Am Heart J 2020 Feb 21. Epub 2020 Feb 21.

University of South Florida Morsani College of Medicine, Department of Internal Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.010DOI Listing
February 2020

Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population.

Am Heart J 2020 Feb 28;224:57-64. Epub 2020 Feb 28.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address:

Background: Critical care risk scores can stratify mortality risk among cardiac intensive care unit (CICU) patients, yet risk score performance across common CICU admission diagnoses remains uncertain.

Methods: We evaluated performance of the Acute Physiology and Chronic Health Evaluation (APACHE)-III, APACHE-IV, Sequential Organ Failure Assessment (SOFA) and Oxford Acute Severity of Illness Score (OASIS) scores at the time of CICU admission in common CICU admission diagnoses. Using a database of 9,898 unique CICU patients admitted between 2007 and 2015, we compared the discrimination (c-statistic) and calibration (Hosmer-Lemeshow statistic) of each risk score in patients with selected admission diagnoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.018DOI Listing
February 2020

Clinical decision support for atrial fibrillation in primary care: Steps forward.

Am Heart J 2020 Mar 19;224:54-56. Epub 2020 Mar 19.

Heart Rhythm Services, Department of Medicine, University of British Columbia, Canada; Center for Cardiovascular Innovation, Vancouver, Canada; Montreal Heart Institute, Department of Medicine, Université de Montréal, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.010DOI Listing

Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.

Am Heart J 2020 Mar 20;224:47-53. Epub 2020 Mar 20.

Department of Medicine, Duke Clinical Research Institute, Center for Preventive Medicine, Duke University, Durham, NC. Electronic address:

Background: The adoption of 2 classes of new diabetes medications, glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i), has been slow in the United States despite their cardiovascular benefits in addition to their glucose-lowering effect. The objective of this study was to identify providers' perspectives about prescribing GLP1RA and SGLT2i.

Methods: In this survey study, a questionnaire was administered between May 17, 2018, and June 11, 2018, in a large academic health care system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.017DOI Listing

Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool.

Am Heart J 2020 Mar 13;224:35-46. Epub 2020 Mar 13.

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Departments of Anesthesia/Pediatrics, McMaster University, Hamilton, Ontario, Canada; Biostatistics Unit, Centre for Evaluation of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute (PHRI), Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Background: Clinical decision support (CDS) tools designed to digest, filter, organize, and present health data are becoming essential in providing clinical and cost-effective care. Many are not rigorously evaluated for benefit before implementation. We assessed whether computerized CDS for primary care providers would improve atrial fibrillation (AF) management and outcomes as compared to usual care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.019DOI Listing

National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective.

Am Heart J 2020 Feb 26;224:25-34. Epub 2020 Feb 26.

Division of Cardiovascular Sciences, NHLBI.

The National Heart, Lung, and Blood Institute (NHLBI) has played an important role in funding the clinical science that supports many contemporary cardiology practice guidelines and in shaping the conduct of cardiovascular clinical trials. This Perspective outlines contemporary funding options as well as select important NHLBI policies, philosophy, and priorities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.014DOI Listing
February 2020

Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.

Am Heart J 2020 Mar 12. Epub 2020 Mar 12.

Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY.

Background: Myocardial infarction (MI) complicated by cardiogenic shock (CS) is associated with high mortality. Early coronary revascularization improves survival, but the optimal mode of revascularization remains uncertain. We sought to characterize practice patterns and outcomes of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in patients with MI complicated by CS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.020DOI Listing

No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial.

Am Heart J 2020 Mar 13;224:17-24. Epub 2020 Mar 13.

Uppsala University Hospital, Uppsala, Sweden.

The SWEDEGRAFT study (ClinicalTrials.gov Identifier: NCT03501303) tests the hypothesis that saphenous vein grafts (SVGs) harvested with the "no-touch" technique improves patency of coronary artery bypass grafts compared with the conventional open skeletonized technique. This article describes the rationale and design of the randomized trial and baseline characteristics of the population enrolled during the first 9 months of enrollment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.009DOI Listing

COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.

Am Heart J 2020 Mar 11;224:10-16. Epub 2020 Mar 11.

Maasstad Hospital, Rotterdam.

Background: Dual antiplatelet therapy constitutes the cornerstone of medical treatment in patients with ST elevation myocardial infarction (STEMI). However, oral antiplatelet agents, such as prasugrel or ticagrelor, are characterized by slow gastrointestinal drug absorption in the acute phase of STEMI, leading to decreased bioavailability and therefore delayed onset of platelet inhibition. Evidence suggests that administration of crushed tablets of the P2Y inhibitor prasugrel improves drug absorption and achieves earlier antiplatelet effects in STEMI patients undergoing primary percutaneous coronary intervention (PCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.005DOI Listing

Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.

Am Heart J 2020 Mar 19;224:1-9. Epub 2020 Mar 19.

National Heart Centre Singapore, Singapore, Singapore; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore; The Hatter Cardiovascular Institute, University College London, London, UK; Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan; Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore; Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico. Electronic address:

Circadian patterns in ST-segment elevation myocardial infarction (STEMI) patients have been previously reported, but little is known about the impact of time dependence of symptom onset on long-term prognosis. Our study population consisted of 11,731 STEMI patients treated by primary percutaneous coronary intervention (PPCI), enrolled in the Singapore Myocardial Infarction Registry (SMIR). Analysis of STEMI incidence trends over the 24-hour period showed the highest rate of symptom onset in the morning, with the peak incidence at 09:00 am. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.011DOI Listing

Smartphone 12-lead ECG-Exciting but must be handled with care.

Am Heart J 2020 Mar 7. Epub 2020 Mar 7.

Clinical Physiology, Skane University Hospital, Department of Clinical Sciences, Lund University, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.03.003DOI Listing

Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: Is it time to regroup?

Am Heart J 2020 May 8;223:106-109. Epub 2020 Feb 8.

Cleveland Clinic, Respiratory Institute, Cleveland, OH.

Background: The diagnosis of cardiac sarcoidosis (CS) is challenging. Because of the current limitations of endomyocardial biopsy as a reference standard, physicians rely on advanced cardiac imaging, multidisciplinary evaluation, and diagnostic criteria to diagnose CS.

Aims: To compare the 3 main available diagnostic criteria in patients clinically judged to have CS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.008DOI Listing

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.

Am Heart J 2020 May 28;223:98-105. Epub 2020 Feb 28.

Duke Clinical Research Institute, Division of Cardiology, Duke University School of Medicine, Durham, NC; Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC.

Background: Ivabradine is guideline-recommended to reduce heart failure (HF) hospitalization in patients with stable chronic HF with reduced ejection fraction (EF). Ivabradine initiation following acute HF has had limited evaluation, and there are few randomized data in US patients. The PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure (PRIME-HF) study was conducted to address predischarge ivabradine initiation in stabilized acute HF patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2019.12.024DOI Listing
May 2020
4.463 Impact Factor

Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.

Am Heart J 2020 May 26;223:87-97. Epub 2020 Feb 26.

Duke University Medical Center, Durham, NC; Clinical Research Institute, Durham, NC.

Background: The evolution and clinical impact of cardiac remodeling after large ST-elevation myocardial infarction (STEMI) is not well delineated in the current therapeutic era.

Methods: The PRESERVATION I trial longitudinally assessed cardiac structure and function in STEMI patients receiving primary percutaneous coronary intervention (PCI). Echocardiograms were performed immediately post-PCI and at 1, 3, 6 and 12 months after STEMI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.017DOI Listing

Adoption of sacubitril-valsartan in the Medicare population.

Am Heart J 2020 May 19;223:81-83. Epub 2020 Feb 19.

Yale New Haven Hospital, Section of Cardiovascular Medicine, New Haven, CT; Center for Outcome Research & Evaluation (CORE), Yale University School of Medicine, New Haven, CT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.009DOI Listing

Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.

Am Heart J 2020 May 24;223:72-80. Epub 2020 Feb 24.

Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China; National Clinical Research Center for Cardiovascular Diseases, Beijing, China. Electronic address:

Background: Quantitative flow ratio (QFR) is a novel angiography-based approach enabling fast computation of fractional flow reserve without use of pressure wire or adenosine. The objective of this investigator-initiated, multicenter, patient- and clinical assessor-blinded randomized trial is to evaluate the efficacy and cost-effectiveness of a QFR-augmented angiography-guided (QFR-guided) strategy versus an angiography-only guided (angiography-guided) strategy for percutaneous coronary intervention (PCI) in patients with coronary artery disease.

Methods: Approximately 3,830 patients will be randomized in a 1:1 ratio to a QFR-guided or an angiography-guided strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.015DOI Listing
May 2020
4.463 Impact Factor

Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.

Am Heart J 2020 May 7;223:65-71. Epub 2020 Jan 7.

Duke Clinical Research Institute, Duke University, Durham, NC. Electronic address:

Background: Obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF). However, it remains unclear whether OSA is independently associated with worse cardiovascular and neurological outcomes in patients with AF.

Methods: We used the ORBIT-AF I and ORBIT-AF II to conduct a retrospective cohort study of 22,760 patients with AF with and without OSA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214210PMC
May 2020
4.463 Impact Factor

Epidemiology of in-hospital cardiac arrest complicating non-ST-segment elevation myocardial infarction receiving early coronary angiography.

Am Heart J 2020 May 29;223:59-64. Epub 2020 Jan 29.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.

In the period between 2000 and 2014, 584,704 admissions with non-ST-segment elevation myocardial infarction that received early coronary angiography (day zero) were identified from the National Inpatient Sample. In-hospital cardiac arrest was noted in 4349 (0.8%), of which ~47% were from ventricular arrhythmias and ~90% of occurred within ≤4 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.016DOI Listing
May 2020
4.463 Impact Factor

Future research prioritization in cardiac resynchronization therapy.

Am Heart J 2020 May 21;223:48-58. Epub 2020 Feb 21.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC; Duke-Margolis Center for Health Policy, Duke University, Durham, NC; Evidence Synthesis Group, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC. Electronic address:

Background: Although cardiac resynchronization therapy (CRT) is effective for some patients with heart failure and a reduced left ventricular ejection fraction (HFrEF), evidence gaps remain for key clinical and policy areas. The objective of the study was to review the data on the effects of CRT for patients with HFrEF receiving pharmacological therapy alone or pharmacological therapy and an implantable cardioverter-defibrillator (ICD) and then, informed by a diverse group of stakeholders, to identify evidence gaps, prioritize them, and develop a research plan.

Methods: Relevant studies were identified using PubMed and EMBASE and ongoing trials using clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.011DOI Listing

A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making.

Am Heart J 2020 May 30;223:44-47. Epub 2020 Jan 30.

Swiss Cardiovascular Center Bern, Bern University Hospital. Electronic address:

The originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-making for dual antiplatelet therapy duration after PCI. It is unknown if a simplified version of the score based on 4 factors (age, hemoglobin, creatinine clearance, prior bleeding), and lacking white-blood cell count, retains potential to guide DAPT duration. The 4-item PRECISE-DAPT was used to categorize 10,081 patients who were randomized to short (3-6 months) or long (12-24 months) DAPT regimen according to high (HBR defined by PRECISE-DAPT ≥25 points) or non-high bleeding risk (PRECISE-DAPT<25) status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.014DOI Listing

Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy.

Am Heart J 2020 May 7;223:34-43. Epub 2020 Feb 7.

Department of Cardiology, University Heart Center Zurich, Switzerland; Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. Electronic address:

Aim: The impact of clinical characteristics for predicting patterns of ventricular involvement in arrhythmogenic right ventricular cardiomyopathy (ARVC) are not well defined. The aims of this study were to characterize different patterns of ventricular involvement in patients with ARVC and to stratify them based on clinical characteristics exercise and underlying genetic mutations.

Methods: Sixty-four patients with definite ARVC from the Swiss ARVC Registry were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.019DOI Listing

Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.

Am Heart J 2020 May 8;223:23-33. Epub 2020 Feb 8.

Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.

Background: Randomized clinical trials demonstrated the efficacy and safety of apixaban in preventing stroke in patients with atrial fibrillation (AF). However, data on patients with low creatinine clearance (CCr), especially CCr 15-29 mL/min, are limited.

Methods: The J-ELD AF Registry is a large-scale, multicenter prospective observational study of Japanese nonvalvular AF patients aged ≥75 years taking on-label dose (standard dose of 5 mg bid or reduced dose of 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.007DOI Listing

Mild sleep restriction increases 24-hour ambulatory blood pressure in premenopausal women with no indication of mediation by psychological effects.

Am Heart J 2020 May 8;223:12-22. Epub 2020 Feb 8.

Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY.

Background: Studies assessing the impact of sleep restriction (SR) on blood pressure (BP) are limited by short study length, extreme SR (<4 hours a night), and lack of attention to psychological distress as a possible mediator.

Methods: A community-based cohort was assembled with 237 women (age 34.1 ± 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.006DOI Listing

Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.

Am Heart J 2020 May 22;223:3-11. Epub 2020 Jan 22.

Janssen Scientific Affairs, Titusville, NJ.

Background: There is limited evidence on the effectiveness and safety of direct-acting oral anticoagulants in patients with nonvalvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD). This study compared the risks of ischemic stroke/systemic embolism (ISSE) and major bleeding in patients with NVAF and stage IV-V CKD treated with rivaroxaban or warfarin.

Methods: Patients with NVAF and stage IV-V CKD who initiated rivaroxaban or warfarin treatment between November 2011 and June 2018 were selected from the Optum® Deidentified Electronic Health Record Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.01.010DOI Listing

Specificity of administrative coding for older adults with acute heart failure hospitalizations.

Am Heart J 2020 May 11;223:1-2. Epub 2020 Feb 11.

Inova Heart and Vascular Institute, Falls Church, VA; Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.004DOI Listing
May 2020
4.463 Impact Factor

Association of postoperative complications and outcomes following coronary artery bypass grafting.

Am Heart J 2020 04 8;222:220-228. Epub 2020 Feb 8.

Department of Surgery, Duke University Medical Center, Durham, NC.

Background: The long-term effects of postoperative complications following coronary artery bypass grafting (CABG) are unknown.

Methods: Medicare-linked records from the Society of Thoracic Surgeons Adult Cardiac Surgery Database were queried for isolated CABG records from 2007 through 2012. Unadjusted and adjusted associations between individual postoperative complications and both mortality and all-cause rehospitalization were evaluated to 7 years using Cox proportional-hazards models and cumulative incidence functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2020.02.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085463PMC